Developing a new method to deliver blood clot-dissolving drugs effectively
Official title: Assembly, Dosimetry, and Assessment of a Platform Technology for the Delivery of Thrombolytics
Funded at Univ of North Carolina Chapel Hill · NIH-11023589 · Data updated 2026-11-12
This study is working on a new way to deliver clot-busting medications more effectively and safely to help people who have had a stroke or heart attack.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project start | January 15, 2025 |
| Project end | December 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $767,077 |
| NIH project number | 1R01HL176666-01 |
| Project ID | NIH-11023589 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients who are at risk of or currently experiencing conditions related to blood clots, such as stroke or myocardial infarction.
✕Less likely to help
Patients with conditions that contraindicate the use of thrombolytic therapy or those who do not have blood clot-related issues may not benefit from this research.
What this research studies
This research focuses on creating an innovative platform for delivering thrombolytic drugs, which are used to dissolve blood clots. By utilizing a combination of natural biomolecules and advanced bioengineering techniques, the team aims to enhance the effectiveness of these drugs while ensuring they are safely delivered to the targeted area in the body. The approach involves using the body's circulatory system as a delivery route, allowing for precise drug release at the site of the clot, potentially improving treatment outcomes for patients with conditions like stroke or heart attack.
Why it matters
Potential benefit: If successful, this research could significantly improve the effectiveness of thrombolytic therapies, leading to better recovery outcomes for patients experiencing blood clots.
How similar studies have gone: Previous research has shown promising results with similar bioengineering approaches in drug delivery, indicating a potential for success in this novel application.
Where this research is happening
-
Univ of North Carolina Chapel Hill
Chapel Hill, United States Active
Researchers
- Principal investigator: Lawrence, David S. — Univ of North Carolina Chapel Hill
- Study coordinator: Lawrence, David S.
Related research
Other NIH-funded projects on the same topics.
-
A center for coordinating data related to heart and blood health.
This study is working on a new system to gather and analyze health information about heart and blood disorders, which could lead to better ways to diagnose and treat these conditions, ultimately helping patients like you.
-
Healthy work design and worker well-being
A multi-site program aims to improve the health and well-being of workers by studying how work design affects safety, stress, and quality of life.
-
Unified and fair multimodal learning for autoimmune diseases
A patient-friendly AI approach will combine many kinds of health data to improve diagnosis and personalized care for autoimmune diseases, including lupus.
-
Structural factors linking minimum wage, COVID-19, and community violence
A long-term study will explore whether higher minimum wages and pandemic-related economic factors are connected to changes in violence in US communities.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
How HPV interacts with our cells' DNA damage system and its effect on cancer
This project looks at how high-risk HPV uses the body’s DNA repair machinery to replicate and potentially drive cancer, with the goal of finding new antiviral and cancer-fighting approaches for people affected by HPV-related diseases.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.